Natera Inc (NAS:NTRA)
$ 162.39 0.4 (0.25%) Market Cap: 21.44 Bil Enterprise Value: 20.99 Bil PE Ratio: 0 PB Ratio: 22.95 GF Score: 70/100

Natera Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 12, 2021 / 08:40PM GMT
Release Date Price: $110.83 (+0.47%)
Tycho W. Peterson
JPMorgan Chase & Co, Research Division - Senior Analyst

All right. We're going to go ahead and get started. I'm Tycho Peterson. It's my pleasure to introduce our next company this afternoon, Natera. (Operator Instructions)

And with that, let me turn it over to Steve.

Steve Chapman
Natera, Inc. - CEO, President & Director

Great. Thanks, Tycho. I'm Steve Chapman. I'm the Chief Executive Officer of Natera. Thank you for having us today.

I'm going to start off on Slide 2. So Natera is, today, the market leader in cell-free DNA technology. We've performed over 3 million tests. We are the leader in peer-reviewed published data, and we have more than 250 technology patents with over 100 issued.

We've come a long way from 2013 when we launched our first cell-free DNA test, Panorama. At that time, we were the fourth to market, and we've grown significantly since then to become the market leader. And we're glad, in 2020, we were able to expand our platform technology, the same technology that took us from fourth

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot